Following the results obtained through the combination of BRAF and MEK inhibitors in BRAF-mutant melanoma [52,53], the same combination was prospectively assessed in BRAF-mutant NSCLC. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.